drugset / Trial / NCT02517502

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502 ↗

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.

Timeline

Start
2015-07
Primary completion
2017-09
Completion
2019-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DHA Unknown 1600 mg —

Indications